Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of SCO-120 in Healthy Volunteers
NCT04242953Phase 1Completed
- Sponsor
- Sun Pharma
- Start
- Mar 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of bexirestrant in breast cancer (3 arms), sponsored by Sun Pharma. Primary endpoint: Number of subjects with treatment-related adverse events as assessed by CTCAE version 5.0 at Day 14. Started Mar 2020; status: completed.
02
Drugs
bexirestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04242953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04242953.